RUBIUS THERAPEUTICS INC's ticker is RUBY and the CUSIP is 78116T103. A total of 120 filers reported holding RUBIUS THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $961,600 | -43.1% | 174,519 | 0.0% | 0.00% | – |
| Q4 2021 | $1,689,000 | -45.9% | 174,519 | 0.0% | 0.00% | -100.0% |
| Q3 2021 | $3,120,000 | -26.8% | 174,519 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $4,260,000 | -57.7% | 174,519 | -54.1% | 0.00% | -50.0% |
| Q1 2021 | $10,070,000 | +194.8% | 380,000 | -15.6% | 0.00% | +100.0% |
| Q4 2020 | $3,416,000 | +51.5% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $2,255,000 | -16.2% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $2,691,000 | +34.3% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $2,003,000 | -53.1% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $4,275,000 | +21.0% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $3,533,000 | -50.1% | 450,000 | 0.0% | 0.00% | -50.0% |
| Q2 2019 | $7,079,000 | -13.1% | 450,000 | 0.0% | 0.00% | -33.3% |
| Q1 2019 | $8,145,000 | +12.6% | 450,000 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $7,236,000 | -33.0% | 450,000 | 0.0% | 0.00% | -25.0% |
| Q3 2018 | $10,800,000 | – | 450,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Pioneering Inc. | 38,296,526 | $290,671,000 | 5.29% |
| HARBOURVEST PARTNERS LLC | 986,878 | $7,490,000 | 2.93% |
| Abbot Financial Management, Inc. | 537,000 | $4,076,000 | 2.35% |
| Artal Group S.A. | 3,778,913 | $28,682,000 | 0.62% |
| HITE Hedge Asset Management LLC | 88,740 | $674,000 | 0.16% |
| Virtus ETF Advisers LLC | 33,793 | $256,000 | 0.11% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 394,909 | $2,997,000 | 0.03% |
| Baillie Gifford | 4,710,061 | $35,749,000 | 0.02% |
| Caption Management, LLC | 86,000 | $652,000 | 0.02% |
| Blueshift Asset Management, LLC | 14,626 | $111,000 | 0.01% |